Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences
Nuvectis Pharma, a biopharmaceutical company focused on developing precision medicines for oncology, announced that CEO Ron Bentsur will present at three investment conferences in September 2022. The first event is the HC Wainwright 24th Annual Global Investment Conference on September 13 at 10:30 a.m. ET in New York, followed by the Cantor Oncology Conference on September 28 at 9:00 a.m. ET, and the Ladenburg Thalmann Healthcare Conference on September 29 at 2:00 p.m. ET. Webcasts of the presentations will be available for 90 days.
- None.
- None.
FORT LEE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences in September.
| Event | HC Wainwright 24th Annual Global Investment Conference |
| Date | September 13, 2022 |
| Time | 10:30 a.m. ET |
| Location | New York |
| Webcast link a | https://journey.ct.events/view/638cef0e-8c84-4cdf-85b0-befd7c815019 |
- A live webcast of the presentation will be available on the link provided for approximately 90 days.
| Event | Cantor Oncology, Hematology & HemeOnc Conference |
| Date | September 28, 2022 |
| Time | 9:00 am ET |
| Location | New York |
| Event | Ladenburg Thalmann 2022 Healthcare Conference |
| Date | September 29, 2022 |
| Time | 2:00 pm ET |
| Location | New York |
| Webcast link a | https://wsw.com/webcast/ladenburg8/nvct/2441476 |
- A live webcast of the presentation will be available on the link provided for approximately 90 days.
About Nuvectis
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, an HSF1-pathway inhibitor, in Phase 1 studies in the EU and U.S., and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling studies. For more information, please visit www.nuvectis.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations, estimates, and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, and other factors that are difficult to predict and include statements regarding the preclinical data generated to date, and the clinical expectations for NXP800 and NXP900 including NXP800's potential ability to become a therapeutic option for the treatment of ovarian clear cell carcinoma, ovarian endometrioid carcinoma and potentially other cancer indications. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are subject to market and other conditions and described more fully in the section titled "Risk Factors" in the 2021 Form 10-K filed with the Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Nuvectis Pharma Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Investor Relations Contact:
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com
FAQ
What is the schedule for Nuvectis Pharma's investor conferences in September 2022?
Where will Ron Bentsur present in September 2022?
How can I access Nuvectis Pharma's conference presentations?
What innovative treatments is Nuvectis Pharma developing?
What is the significance of the investor conferences for NVCT stock?
